$1.52 Billion is the total value of Bellevue Group AG's 138 reported holdings in Q4 2018. The portfolio turnover from Q3 2018 to Q4 2018 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| MDT | MEDTRONIC PLC | $45,157,000 | -7.5% | 496,446 | 0.0% | 2.97% | -4.2% | |
| ZBH | ZIMMER BIOMET HLDGS INC | $9,553,000 | -21.1% | 92,104 | 0.0% | 0.63% | -18.2% | |
| IDXX | IDEXX LABS INC | $4,522,000 | -25.5% | 24,307 | 0.0% | 0.30% | -22.9% | |
| XRAY | DENTSPLY SIRONA INC | $4,126,000 | -1.4% | 110,878 | 0.0% | 0.27% | +2.3% | |
| HSIC | SCHEIN HENRY INC | $4,033,000 | -7.7% | 51,368 | 0.0% | 0.26% | -4.3% | |
| CERN | CERNER CORP | $3,102,000 | -18.6% | 59,146 | 0.0% | 0.20% | -15.7% | |
| AMED | AMEDISYS INC | $2,952,000 | -6.3% | 25,204 | 0.0% | 0.19% | -3.0% | |
| JNJ | JOHNSON & JOHNSON | $2,581,000 | -6.6% | 20,000 | 0.0% | 0.17% | -2.9% | |
| ANGO | ANGIODYNAMICS INC | $1,524,000 | -7.4% | 75,700 | 0.0% | 0.10% | -3.8% | |
| PODD | INSULET CORP | $1,428,000 | -25.1% | 18,000 | 0.0% | 0.09% | -22.3% | |
| AMRX | AMNEAL PHARMACEUTICALS INC | $1,285,000 | -39.0% | 95,000 | 0.0% | 0.08% | -37.3% | |
| RGNX | REGENXBIO INC | $977,000 | -44.5% | 23,300 | 0.0% | 0.06% | -42.9% | |
| TEVA | TEVA PHARMACEUTICAL INDS LTDsponsored adr | $925,000 | -28.4% | 60,000 | 0.0% | 0.06% | -25.6% | |
| HCSG | HEALTHCARE SVCS GRP INC | $603,000 | -1.0% | 15,000 | 0.0% | 0.04% | +2.6% |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
- Bellevue Asset Management AG #1
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2019-02-12
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| IONIS PHARMACEUTICALS INC | 31 | Q3 2023 | 9.3% |
| Vertex Pharmaceuticals Incorporated | 31 | Q3 2023 | 5.9% |
| NEUROCRINE BIOSCIENCES INC | 31 | Q3 2023 | 5.7% |
| Incyte Corporation | 31 | Q3 2023 | 5.4% |
| INTUITIVE SURGICAL INC | 31 | Q3 2023 | 4.7% |
| ABBOTT LABS | 31 | Q3 2023 | 4.6% |
| ELEVANCE HEALTH INC | 31 | Q3 2023 | 4.3% |
| UnitedHealth Group Incorporated | 31 | Q3 2023 | 3.6% |
| ALNYLAM PHARMACEUTICALS INC | 31 | Q3 2023 | 3.7% |
| Boston Scientific Corporation | 31 | Q3 2023 | 2.5% |
View Bellevue Group AG's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-15 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| 13F-HR | 2023-02-14 |
| SC 13G | 2023-02-14 |
| SC 13G | 2023-02-14 |
View Bellevue Group AG's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.